{"disease":{"id":"upper-tract-urothelial-carcinoma","name":"upper tract urothelial carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07077447","title":"The Danish Bladder Cancer Group 23 Study - A European Study on Cancer in the Upper Urinary Tract","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Zealand University Hospital","has_results":false},{"nct_id":"NCT06169436","title":"Translational Cancer Observational Protocol","phase":"","overall_status":"RECRUITING","enrollment_count":1250,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT04948528","title":"Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for Upper Tract Urothelial Carcinoma Detection","phase":"","overall_status":"UNKNOWN","enrollment_count":490,"lead_sponsor_name":"AnchorDx Medical Co., Ltd.","has_results":false},{"nct_id":"NCT05810623","title":"Single-Dose Intravesical Chemotherapy After Diagnostic URS","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":394,"lead_sponsor_name":"David D'Andrea","has_results":false},{"nct_id":"NCT06798246","title":"HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT07498907","title":"Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":192,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT07321210","title":"Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC): A Randomized Clinical Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT06040762","title":"A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT07492225","title":"Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT06204406","title":"Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":106,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT05595408","title":"Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT03230201","title":"Lymph Node Dissection in High-risk UTUC(Upper Tract Urothelial Carcinoma)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT06210490","title":"A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT07584733","title":"Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT07225374","title":"Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT07492628","title":"Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT03544437","title":"Feasibility and Safety of Extraperitoneal Laparoscopic Extended Retroperitoneal Lymph Node Dissection at Time of Nephroureterectomy for Upper Tract Urothelial Carcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT04197986","title":"Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":39,"lead_sponsor_name":"QED Therapeutics, a BridgeBio company","has_results":true},{"nct_id":"NCT02412670","title":"Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":true},{"nct_id":"NCT07504939","title":"Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT07126119","title":"Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT03617003","title":"Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05160285","title":"Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":29,"lead_sponsor_name":"YULISU","has_results":false},{"nct_id":"NCT05912816","title":"Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT04672317","title":"Neoadjuvant PD-1 Monoclonal Antibody Plus Cisplatin-based Chemotherapy in Locally Advanced Upper Tract Urothelial Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT04944550","title":"New Models for the Evaluation of Preclinical Treatment for Urothelial Carcinomas of the Upper Excretory Tract.","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT06668493","title":"Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Ferring Pharmaceuticals","has_results":false},{"nct_id":"NCT06354231","title":"DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04672330","title":"Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06848868","title":"Ambulatory Flexible URS for UTUC Surveillance","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false}],"total":30},"guidelines":[],"source":"Drug Landscape verified database"}